Ampio to implement fifteen-to-one reverse stock split

Ampio Pharmaceuticals announced that effective November 9, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split. As a result of the reverse stock split, every fifteen shares of common stock issued and outstanding automatically will be combined into one share of common stock, with no change in the 0.01c par value per share. No fractional shares will be outstanding following the reverse stock split. Holders of fractional shares will be entitled to receive the number of shares rounded up to the next whole number. Immediately prior to the reverse stock split, the Company had 226,286,867 shares of common stock outstanding, which will be proportionately reduced to reflect the fifteen-to-one reverse stock split. The reverse stock split will not change the number of authorized shares under the Company’s certificate of incorporation, which will continue to consist of 310,000,000 shares authorized, of which 10,000,000 shares are designated as preferred stock and 300,000,000 shares are designated as common stock. The Company is implementing the reverse stock split in order to attempt to increase the per share price of its common stock as part of its strategy to seek the termination of the trading suspension on the NYSE American, so that trading may resume on that market. The CUSIP identifier for the Company’s common stock following the reverse stock split is 03209T 208. The Company’s common stock will begin trading on a post-split basis, on the OTC Pink Open Market, when the market opens on November 10.